News
FORMER DIRECTOR GENERAL OF THE ITALIAN MEDICINES AGENCY (AIFA) DR. LUCA PANI JOINS NEUROCOG TRIALS
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and...
read moreNCT Linguistics Sponsors Triangle Biotech Tuesday – Press Release
DURHAM, NORTH CAROLINA, May 19, 2017 NCT Linguistics, a leading global provider of translation, interpretation, and training services, was honored to sponsor Triangle Biotech Tuesday in Research Triangle Park on Tuesday, May 9, 2017. Triangle Biotech Tuesday is a...
read moreNCT Linguistics and NeuroCog Trials Expand Workforce, Office Space At Durham Headquarters
DURHAM, NC, Nov. 30, 2016 — NeuroCog Trials, the leading cognitive services provider for the clinical trials industry, today announced that it is significantly expanding its presence at its headquarters in Durham. Construction is currently underway to give NeuroCog...
read moreNCT Linguistics and Percept Research Announce Partnership – Press Release
NCT Linguistics becomes the exclusive provider of translation services for Percept Research DURHAM, NORTH CAROLINA, October 10, 2016 – NCT Linguistics, the boutique language solutions provider, today announced that it has signed an exclusive agreement with Percept...
read moreCognitive Dysfunction as a Treatment Target in Depression
NeuroCog Trials welcomes the outcome of the FDA Psychopharmacologic Drug Advisory Committee meeting that cognitive dysfunction in Major Depressive Disorder (MDD) represents an appropriate drug development target. The issue was discussed at the meeting on February 3rd...
read moreNeuroCog Trials, Inc. announces work supporting a major pharmaceutical company clinical trial to assess performance based skills assessment in patients with major depression.
Durham, NC—July 1, 2014— NeuroCog Trials, Inc. announces that it has begun work supporting a major pharmaceutical company clinical trial to assess performance- based skills assessment in patients with major depression. The trial will examine the effects of active drug...
read moreNeuroCog Trials, Inc. announces a new method established for reviewing administration procedures and data collection for the Alzheimer’s Disease Assessment Scale (ADAS-Cog).
NeuroCog Trials, Inc. announces that a new method has been established for reviewing administration procedures and data collection for the Alzheimer’s Disease Assessment Scale (ADAS-Cog). This method will be utilized by a large pharmaceutical company for a new...
read moreNeuroCog Trials, Inc. announces support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker risk assignment algorithm to predict risk of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five year period.
NeuroCog Trials, Inc. announces that they have begun providing support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker Trial Press Release: NeuroCog Trials, Inc. announces support for the cognitive...
read moreNeuroCog Trials, Inc. Reaches 100 Full Time Employees
NeuroCog Trials, Inc. announces that it has grown to 100 full time employees. Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, said, “The mission of NeuroCog has always been to provide high quality cognitive methodologies for our sponsors and the patients...
read moreTrial Press Release: NeuroCog Trials, Inc. announces work supporting a pharmaceutical company clinical trial to assess cognition in patients with chronic kidney disease.
NeuroCog Trials, Inc. announces that they have begun work supporting a pharmaceutical company clinical trial to assess cognition in patients with chronic kidney disease. The trial will examine the effects of active drug treatment versus placebo on standard...
read more